Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
about
Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMPCross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particlePreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineChimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 virusesVirus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.Mucosal immunization in perspective.Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.Heterosubtypic cross-protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administrationAntiviral B cell and T cell immunity in the lungs.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsEvaluation of influenza-specific humoral response by microbead array analysisOral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.Sublingual vaccination with influenza virus protects mice against lethal viral infection.Influenza B vaccine lineage selection--an optimized trivalent vaccine.Mucosal vaccine development for botulinum intoxication.Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 virusesBacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applicationsIntranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.Aging affects human B cell responses.Mucosal immunity and nasal influenza vaccination.Small intestinal injury in mice infected with respiratory influenza A virus: evidence for virus induced gastroenteritis.H1N1 infection associated with persistent lower respiratory tract illness in an infant with isolated IgA deficiency.Oral immunization of a non-recombinant Lactococcus lactis surface displaying influenza hemagglutinin 1 (HA1) induces mucosal immunity in mice.Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice.Cross-Protective Efficacy of Monovalent Live Influenza B Vaccines against Genetically Different Lineages of B/Victoria and B/Yamagata in Ferrets
P2860
Q21090975-537FFF26-5911-42A6-8C46-B35ECC8F0A55Q21562299-D9F838DF-8543-4A38-A120-529682A4FA73Q27347652-E33D8487-2561-4AF4-B533-314BF7DCE825Q28365124-D8D882A1-97CA-4F90-A1CD-D3EE1CB2348DQ30359424-F1560C6F-A54A-4113-B4AF-4D697BD49119Q30368932-1F736D3C-5A2E-4343-BEC1-2B9A1715B8A8Q30374752-325E107B-E6AA-4A7A-A501-6B292934D27DQ33958402-DB2765BB-A55D-4C53-92B6-ADE969B69812Q34454614-26B87C31-05B4-42BC-87C0-472A653E2306Q34641666-5EA5450D-3632-467F-84A0-948ACDBF3E10Q34789793-9CE0F8ED-EA5C-45EC-A734-26E30E444769Q36087562-EB3FD90D-2EBC-43DB-8B11-D47AB8D42904Q36173746-DC8D79D7-786F-44F1-8169-B5644F9022F1Q36239573-5B794008-A1B1-4D29-BBF9-800B6D81CD59Q36446440-BACB55B1-C122-46E4-94FC-C226A162F447Q36690569-D254A1EB-9754-4090-AFD3-F65CE849C922Q36728788-10228AC4-F156-4898-A1C7-8FE0AF3A2A11Q37018558-89191D8A-FE1A-417C-B461-99ED6A3F19DBQ37177598-FD199893-8DF4-4634-9318-95A2483FA81CQ37530383-66CF0E4A-437D-46DC-BB28-508A8D5B0929Q37547653-2161F157-6542-45BA-A16B-1C1212563AFEQ37841206-B71FA5AA-463E-4DF6-8BA1-F190ABDD6C87Q38028996-153E7582-FD09-422D-861C-B58B3DC80BCBQ41237008-8B7647B0-4208-434C-A831-2094DF46615BQ42618843-465F8145-F34F-4EC1-8159-75454BE03514Q45391504-0D1DD5F1-50AB-4CD0-A787-BDDB3BDEC9C4Q47548928-B04061A2-5053-4424-86C5-04893BBF86D1Q47555103-EC1AAF3F-6652-47E8-8906-932838A8D803Q50772737-6E8A3B3D-D319-4443-BB01-F3C562EA5805Q56993913-D90A6AAA-6265-4D80-93B5-CA9E870283A8
P2860
Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Secretory IgA antibodies provi ...... strains of influenza B virus.
@en
Secretory IgA antibodies provi ...... strains of influenza B virus.
@nl
type
label
Secretory IgA antibodies provi ...... strains of influenza B virus.
@en
Secretory IgA antibodies provi ...... strains of influenza B virus.
@nl
prefLabel
Secretory IgA antibodies provi ...... strains of influenza B virus.
@en
Secretory IgA antibodies provi ...... strains of influenza B virus.
@nl
P2093
P50
P356
P1476
Secretory IgA antibodies provi ...... strains of influenza B virus.
@en
P2093
Shin-Ichi Tamura
Takeshi Kurata
Yasuko Asahi-Ozaki
Yujiro Suzuki
P2860
P304
P356
10.1002/JMV.20173
P577
2004-10-01T00:00:00Z